SCHEMBL21497086

SCHEMBL21497086

COc1ccc2c(c1C(=O)O)OB(O)CC2CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 6/20 0.41
▸ CA1 P00915 5/20 0.41
▸ CA9 Q16790 5/20 0.41
▸ CA12 O43570 3/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ CAT P04040 1/20 0.35
▸ PPARA Q07869 1/20 0.34
▸ KDM4C Q9H3R0 1/20 0.33
▸ TBXAS1 P24557 1/20 0.32
▸ SMN1; SMN2 Q16637 3/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX5 P09917 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ GAA P10253 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ GFER P55789 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21503787 1.00 CA2 (0.41) CA2CA1CA9CA12CA7
SCHEMBL21497094 1.00 CA2 (0.41) CA2CA1CA9CA12CA7
SCHEMBL21497098 0.91 CA2 (0.39) CA2CA1CA9CA12CA7
SCHEMBL27270456 0.91 CA2 (0.39) CA2CA1CA9CA12CA7
SCHEMBL27268842 0.90 CA9 (0.41) CA2CA1CA9CA12CA7
SCHEMBL21497091 0.89 CA1 (0.40) CA2CA1CA9CA12CA7
SCHEMBL21497099 0.89 CA12 (0.40) CA2CA1CA9CA12CA7
SCHEMBL21497093 0.85 MTNR1A (0.43) CA2CA1CA9CA12CA7
SCHEMBL21497100 0.84 CA12 (0.36) CA2CA1CA9CA12CA7
SCHEMBL27268429 0.84 CAT (0.37) CAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240307422-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF QPEX BIOPHARMA INC (US) 2024-09-19 — — US disclosed
US-12016868-B2 Boronic acid derivatives and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2024-06-25 — — US disclosed
US-12016868-B2 Boronic acid derivatives and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2024-06-25 — — US disclosed
US-12016868-B2 Boronic acid derivatives and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2024-06-25 — — US disclosed
EP-3781576-B1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF QPEX BIOPHARMA INC (US) 2024-06-12 — — EP disclosed
US-20210361682-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF QPEX BIOPHARMA, INC. 2021-11-25 — — US disclosed
US-20210361682-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF QPEX BIOPHARMA, INC. 2021-11-25 — — US disclosed
EP-3781576-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF QPEX BIOPHARMA, INC. (US) 2021-02-24 — — EP disclosed
WO-2019204419-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF THE MEDICINES COMPANY (SAN DIEGO), LLC (US) 2019-10-24 — — WO disclosed
WO-2019204419-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF THE MEDICINES COMPANY (SAN DIEGO), LLC (US) 2019-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240307422-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF BCL6B, BCL6, BTD CA2 244/4885CA1 1095/4885CA9 43/4885
US-12016868-B2 Boronic acid derivatives and therapeutic uses thereof BCL6B, BCL6, BTD CA2 229/4885CA1 1170/4885CA9 52/4885
US-20210361682-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF BCL6B, BCL6, BTD CA2 229/4885CA1 1170/4885CA9 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback